Estarylla Birth Control Pill Recall Issued Due to Packaging Error

|

A packaging error found in a blister pack of Estarylla birth control pills has led Sandoz USA to issue a recall, due to the potential risk that women may take placebos instead of the active tablets, leaving them unprotected against pregnancy. ย 

The FDA announced the Estarylla recall on July 3, after a customer reported that at least one placebo tablet was in the incorrect row, mixed in with the active tablets. The recall will be issued at the retail level.

So far, this is the only incident reported by the company, however the recall was issued for the entire lot as a precaution. Sandoz says no adverse affects have been reported as a result of the error, and maintains that the risk of pregnancy from the packaging error is low, considering the flaw is easily visible before consuming the product.

Spinal-Cord-Stimulation-Lawsuit
Spinal-Cord-Stimulation-Lawsuit

Estarylla is manufactured for Sandoz by a third party manufacturer. Sandoz is a division of Novartis.

The recalled Estarylla (norgestimate and ethinyl estradiol) pills come from lot number LF01213A, with expiration date 02/2014 and NDC 00781-4058-15. It is supplied in cartons containing 3 blister cards of 28 tablets each, which was distributed within the US market only.

Ongoing Birth Control Manufacturing Problems

The Sandoz recall is one of many in a string of recent birth control pill recalls issued due to manufacturing problems that may leave women exposed to a risk of unwanted pregnancy.

Last month, Johnson & Johnson issued a recall of Cilest birth control pills after finding the drug had solubility issues, rendering it ineffective. Testing that led to the recall found one of the key active ingredients may dissolve too slowly. The ineffectiveness could result in unplanned pregnancy, with more than 32 million packages of birth control pills affected by the recall.

Earlier this year, a product liability lawsuit was filed against Qualitest Pharmaceuticals by a Missouri woman alleging she became pregnant after taking ineffective birth control pills manufactured by Qualitest which were a part of a 2011 recall. Those birth control pills were recalled after it was discovered that certain lots of Cyclafem 7/7/7, Cyclafem 1/35, Emoquette, Gildess FE 1.5/30, Gildess FE 1/20, Orsythia, Previfem and Tri-Previfem were packaged in reverse order, causing some women to take the pills in the incorrect order. The incorrect packaging placed the women at risk of pregnancy.

Officials recommend customers who are taking Estarylla birth control tablets contact their health care provider immediately if they feel they are at risk or have taken pills from a flawed package. Customers with questions can call the Sandoz Drug Information Direct Line at (800) 525-2492 or send an email to qa.druginfo@sandoz.com.

Written by: Martha Garcia

Health & Medical Research Writer

Martha Garcia is a health and medical research writer at AboutLawsuits.com with over 15 years of experience covering peer-reviewed studies and emerging public health risks. She previously led content strategy at The Blogsmith and contributes original reporting on drug safety, medical research, and health trends impacting consumers.

Image Credit: |



1 Comments


Maya
I was just hospitalized for two days with blood clots in my right leg and both lungs. All of which I still have and Iโ€™m not yet released to go back to work. I got the clots from this birth control that I recently had started. I have no history nor family history of clots and now I will be on a blood thinner all my life not only that but now in the future when I want kids it will be difficult.

This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

An Illinois woman has joined a growing number of plaintiffs alleging that the Medtronic Intellis neurostimulator, and similar devices, may fail to relieve chronic pain and instead lead to worsening complications.
A federal judge is being asked to certify seven hair relaxer class action lawsuits seeking medical monitoring for users, following studies that link the products to an increased risk of cancer.